What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study

What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study

BACKGROUND:It is unclear what to do when people with type 2 diabetes have had no or a limited glycemic response to a recently introduced medication. Intra-individual HbA1c variability can obscure true response. Some guidelines suggest stopping apparently ineffective therapy, but no studies have addr...

Bibliografske podrobnosti
Main Authors:	McGovern, A, Dennis, J, Shields, B, Hattersley, A, Pearson, E, Jones, A, Mastermind Consortium
Drugi avtorji:	Farmer, A
Format:	Journal article
Jezik:	English
Izdano:	BioMed Central 2019

Podobne knjige/članki

What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
od: Andrew P. McGovern, et al.
Izdano: (2019-04-01)

Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?
od: Angus G Jones, et al.
Izdano: (2016-01-01)

Costs and treatment pathways for type 2 diabetes in the UK: a Mastermind Cohort study
od: Eibich, U, et al.
Izdano: (2017)

Mastermind ophthalmology
od: Madhav
Izdano: (2007-01-01)

Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
od: Agbaje, O, et al.
Izdano: (2017)

Fructosamine and HbA1c
od: Kurumbian Chandran, et al.
Izdano: (2024-02-01)

Oliver heaviside : maverick mastermind of electricity /
od: 309384 Mahon, Basil
Izdano: (2009)

Use of HbA1c in the diagnosis of diabetes.
od: Farmer, A
Izdano: (2012)

Artifactually lowered glycosylated hemoglobin (HbA1c %) in patient with diabetes on dapsone
od: Amit Rastogi, et al.
Izdano: (2012-01-01)

What are the HbA(1c) thresholds for initiating insulin therapy in people with type 2 diabetes in UK primary care?
od: Hinton, W, et al.
Izdano: (2016)

Predictors of HbA1c treatment response to add-on medication following metformin monotherapy: a population-based cohort study
od: Wei Ying Tan, et al.
Izdano: (2023-11-01)

HbA1C and diabetes – an overview
od: S Pathmanathan, et al.
Izdano: (2014-01-01)

A new 6.111 laboratory exercise : Mastermind
od: Mahn, Nathan A. (Nathan Aaron), 1979-
Izdano: (2014)

High-performance liquid chromatography local reference ranges of hemoglobin fractions (HbA, HbA2, and HbF) in detection of hemoglobinopathies in western Kenya
od: Benard Mutua, et al.
Izdano: (2022-12-01)

The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables.
od: Marcus Lind, et al.
Izdano: (2009-01-01)

Epstein-Barr virus: the mastermind of immune chaos
od: Jean de Melo Silva, et al.
Izdano: (2024-02-01)

The Exact Query Complexity of Yes-No Permutation Mastermind
od: Mourad El Ouali, et al.
Izdano: (2020-04-01)

Mumbai Investigation: The Operatives, Masterminds and Enduring Threat
od: Rohan Gunaratna
Izdano: (2009-01-01)

Selective Phenotyping, Entropy Reduction, and the Mastermind game
od: Gagneur Julien, et al.
Izdano: (2011-10-01)

The Paradox of Help Seeking in the Entropy Mastermind Game
od: Nichola Taylor, et al.
Izdano: (2020-09-01)

Liraglutide, a human GLP-1 analogue, lowers HbA(1c) independent of weight loss
od: Schmidt, W, et al.
Izdano: (2009)

Influence of Serum Albumin on HbA1c and HbA1c-Defined Glycemic Status: A Retrospective Study
od: Xiaojing Feng, et al.
Izdano: (2021-05-01)

Liraglutide Is Associated with Reduced Rates of Hypoglycemic Events Versus Glimepiride When Achieving Target HbA(1c)
od: Gough, S, et al.
Izdano: (2010)

Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease
od: Mostafa, SA, et al.
Izdano: (2017)

Effects of thyroid status on HbA1c
od: Sivaranjani Ambalavanan, et al.
Izdano: (2024-11-01)

Drugs affecting HbA1c levels
od: Ranjit Unnikrishnan, et al.
Izdano: (2012-01-01)

Current Status of HbA1c Biosensors
od: Hua Lin, et al.
Izdano: (2017-08-01)

Hemoglobin variants detected by hemoglobin A1c (HbA1c) analysis and the effects on HbA1c measurements.
od: Nasir, N.M., et al.
Izdano: (2010)

Sleep characteristics and HbA1c in patients with type 2 diabetes on glucose-lowering medication
od: Christian Benedict
Izdano: (2020-04-01)

Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors
od: Kurukulasuriya L Romayne, et al.
Izdano: (2010-08-01)

Death of Bahrun Naim : Mastermind of Terror in Southeast Asia
od: Gunaratna, Rohan
Izdano: (2018)

“Evil Mastermind” in the framework of a verbally modeled reality
od: Oleksandr Kolesnyk, et al.
Izdano: (2022-12-01)

Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes: a cohort study
od: Lauren R. Rodgers, et al.
Izdano: (2021-08-01)

Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy
od: Katherine G. Young, et al.
Izdano: (2023-11-01)

Glycated haemoglobin - when can we trust it? Analysis of factors affecting the HbA1c level
od: Marcin Lewicki, et al.
Izdano: (2018-12-01)

Glycated haemoglobin - when can we trust it? Analysis of factors affecting the HbA1c level
od: Marcin Lewicki, et al.
Izdano: (2018-12-01)

Haemoglobin types and variant interference with HbA1c and its association with uncontrolled HbA1c in type 2 diabetes mellitus
od: Joseph Malaba, et al.
Izdano: (2024-11-01)

Symposium 3: HbA1c: Are HbA1c determinations reliable enough today in Argentina to adopt them as diagnostic criteria?
od: Carla Lucarelli
Izdano: (2022-09-01)

Understanding the relationship between the frequency of HbA1c monitoring, HbA1c changes over time, and the achievement of targets: a retrospective cohort study
od: Elton Mukonda, et al.
Izdano: (2025-01-01)

HbA1c in patients with glioblastomas - a preliminary study
od: D. Orešković, et al.
Izdano: (2022-01-01)